Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania.

IF 5.2 Q1 DERMATOLOGY Psoriasis (Auckland, N.Z.) Pub Date : 2024-06-25 eCollection Date: 2024-01-01 DOI:10.2147/PTT.S456393
Stefana Bucur, Elena-Daniela Serban, Bogdan Vasile Ileanu, Raluca Simona Costache, Alin Codrut Nicolescu, Traian Constantin, Daniel Octavian Costache, Maria-Magdalena Constantin
{"title":"Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania.","authors":"Stefana Bucur, Elena-Daniela Serban, Bogdan Vasile Ileanu, Raluca Simona Costache, Alin Codrut Nicolescu, Traian Constantin, Daniel Octavian Costache, Maria-Magdalena Constantin","doi":"10.2147/PTT.S456393","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Multiple biological therapies have been developed for the treatment of inflammatory diseases, including moderate to severe plaque psoriasis. Choosing the optimal treatment for psoriasis can depend on several factors and is strongly influenced by a drug's efficacy and safety profile. Continuous treatment with biological therapies is recommended to achieve effective disease management in patients with psoriasis. However, in real-world, patients often discontinue biologic therapy within the first year of treatment. Therefore, in this study, we aimed to investigate the effectiveness and drug survival of two anti-interleukin 17 agents (ixekizumab and secukinumab) in a group of adult patients with moderate to severe psoriasis from Bucharest, Romania.</p><p><strong>Patients and methods: </strong>We designed an observational, non-interventional, retrospective study of 255 adult patients with moderate to severe psoriasis receiving ixekizumab and secukinumab. We performed descriptive statistics and inferential methods, such as z-test, median test and Kaplan Meier curve comparison, to characterize the groups with two biological treatments.</p><p><strong>Results: </strong>Patients treated with ixekizumab had a longer drug survival compared to those treated with secukinumab with lower risks of non-persistence, discontinuation and switching therapy. Patients age-groups and psoriasis durations found to be significant factors in drug survival.</p><p><strong>Conclusion: </strong>This study contributes to the understanding of the drug survival profile and the factors that may influence it in ixekizumab and secukinumab treatment in a real-world setting.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"14 ","pages":"79-86"},"PeriodicalIF":5.2000,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11214564/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psoriasis (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/PTT.S456393","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Multiple biological therapies have been developed for the treatment of inflammatory diseases, including moderate to severe plaque psoriasis. Choosing the optimal treatment for psoriasis can depend on several factors and is strongly influenced by a drug's efficacy and safety profile. Continuous treatment with biological therapies is recommended to achieve effective disease management in patients with psoriasis. However, in real-world, patients often discontinue biologic therapy within the first year of treatment. Therefore, in this study, we aimed to investigate the effectiveness and drug survival of two anti-interleukin 17 agents (ixekizumab and secukinumab) in a group of adult patients with moderate to severe psoriasis from Bucharest, Romania.

Patients and methods: We designed an observational, non-interventional, retrospective study of 255 adult patients with moderate to severe psoriasis receiving ixekizumab and secukinumab. We performed descriptive statistics and inferential methods, such as z-test, median test and Kaplan Meier curve comparison, to characterize the groups with two biological treatments.

Results: Patients treated with ixekizumab had a longer drug survival compared to those treated with secukinumab with lower risks of non-persistence, discontinuation and switching therapy. Patients age-groups and psoriasis durations found to be significant factors in drug survival.

Conclusion: This study contributes to the understanding of the drug survival profile and the factors that may influence it in ixekizumab and secukinumab treatment in a real-world setting.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Ixekizumab 和 Secukinumab 对中重度斑块状银屑病患者的疗效和药物存活率:来自罗马尼亚布加勒斯特的真实世界数据。
目的:目前已开发出多种生物疗法用于治疗炎症性疾病,包括中度至重度斑块状银屑病。选择银屑病的最佳治疗方法取决于多种因素,并受到药物疗效和安全性的强烈影响。为了有效控制银屑病患者的病情,建议持续使用生物疗法。然而,在现实世界中,患者往往会在治疗的第一年内中断生物疗法。因此,在这项研究中,我们旨在调查两种抗白细胞介素 17 药物(ixekizumab 和 secukinumab)在罗马尼亚布加勒斯特一组中重度银屑病成年患者中的疗效和药物存活率:我们设计了一项观察性、非干预性、回顾性研究,研究对象是 255 名接受 ixekizumab 和 secukinumab 治疗的中重度银屑病成年患者。我们采用了描述性统计和推理方法,如z检验、中位数检验和卡普兰-梅尔曲线比较,来描述接受两种生物治疗的群体的特征:结果:与使用secukinumab治疗的患者相比,使用ixekizumab治疗的患者的药物存活期更长,不持续、中断和转换疗法的风险更低。患者年龄组和银屑病病程是影响药物存活率的重要因素:这项研究有助于了解在真实世界环境中,ixekizumab和secukinumab治疗的药物存活情况以及可能影响药物存活的因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
期刊最新文献
Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review. A New Prescription Emollient Device (PED) For Psoriasis of Sensitive Areas and Folds: A Randomized Prospective Open Trial. Psoriasis Flare Following Paramyxovirus Infection. Metabolic Syndrome in Psoriasis and Psoriatic Arthritis in a Mixed Race Population: Comparison of Their Prevalences. Do NSAIDs Trigger or Exacerbate Psoriasis? [Response to Letter].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1